Neuphoria receives AUD 1.416M CTx CRC payment; eligible for ~4.65% of $460M milestones

Neuphoria Therapeutics Inc.

Received AUD 1.416M from CTx CRC upon Pfizer's Phase III start in ER+/HER2- metastatic breast cancer.
Believes eligible for ~4.65% of future milestone payments from CTXT, total estimated at USD 460M across all parties.
Total distributions received from CTx CRC since 2016: AUD 3.52M.
Historical licensing revenues include AUD 967K from MSD (PRMT5) in 2016 and multiple Pfizer-related payments.
Company is a passive party and cannot determine whether future milestones will be achieved or payment amounts.

item 8.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-26-061028
form_type: 8-K
ticker: NEUP
cik: 0001191070
company_name: Neuphoria Therapeutics Inc.
filed_at: 2026-05-26T20:15:40+00:00
discovered_at: 2026-05-26T20:18:01.515648+00:00
generated_at: 2026-05-26T20:33:27.755080+00:00
sec_items: ["8.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-26-061028
json_url: https://secwatch.observer/filing/0001213900-26-061028.json
markdown_url: https://secwatch.observer/filing/0001213900-26-061028.md
text_url: https://secwatch.observer/filing/0001213900-26-061028.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1191070/000121390026061028/0001213900-26-061028-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1191070/000121390026061028/ea0292160-8k_neuphoria.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001213900-26-061028

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.